ATTO (Attovia Therapeutics) Research & Development: $16.75 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.38
View Full Analysis

What is Attovia Therapeutics Research & Development?

Attovia Therapeutics ATTO -6.94% 8 Research & Development is $16.75 Mil as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Research & Development is the aggregate amount of research and development expenses during the year. Attovia Therapeutics's Research & Development for the three months ended in Mar. 2026 was $16.75 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $16.75 Mil.

Attovia Therapeutics  (NAS:ATTO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Attovia Therapeutics Research & Development Related Terms

Attovia Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics Research & Development Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
Research & Development
33.86 54.15

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Research & Development 0.00 11.86 0.00 16.75
ATTO
8GF Score
Attovia Therapeutics Inc ATTO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Attovia Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $16.75 Mil mean?
Attovia Therapeutics (ATTO) has a Research & Development of $16.75 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Attovia Therapeutics and its competitors.
Is Attovia Therapeutics' Research & Development too high?
Attovia Therapeutics' current Research & Development is $16.75 Mil. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Research & Development compare to ?
Attovia Therapeutics' Research & Development of $16.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Attovia Therapeutics and its competitors. Attovia Therapeutics's current Research & Development is $16.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Research & Development of $16.75 Mil. The current Research & Development is $16.75 Mil. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Research & Development is $16.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.38
Price